読み込み中
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
前日終値
$0.9555
−$0.0219 · -2.24%
日中の時刻はETです。市場データは遅延する場合があります。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日中レンジ
現在 $0.9555
52週レンジ
現在 $0.9555
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
37
割高
センチメント
49
まちまち
リスク
74
高リスク
モメンタム
38
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日中レンジ
現在 $0.9555
52週レンジ
現在 $0.9555
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 441.3万 USD | 405.5万 USD | 603.6万 USD | 248.8万 USD | — |
| 売上原価 | 238.9万 USD | 196.8万 USD | 70.4万 USD | — | — |
| 粗利益 | 202.4万 USD | 208.7万 USD | 533.2万 USD | 248.8万 USD | — |
| 研究開発 | 3975万 USD | 3212.6万 USD | 3957.3万 USD | 5615.9万 USD | 3510.8万 USD |
| 販売・一般管理 | 2757.9万 USD | 2668.6万 USD | 3199.4万 USD | 3540万 USD | 2292万 USD |
| 営業費用 | 6494万 USD | 5684.4万 USD | 7086.3万 USD | 9155.9万 USD | 5802.8万 USD |
| 受取利息 | 92.2万 USD | 130万 USD | 250万 USD | 140万 USD | — |
| 支払利息 | 518.8万 USD | — | — | — | 7.9万 USD |
| 減価償却費と償却費 | 238.9万 USD | 196.8万 USD | 70.4万 USD | 48万 USD | 22.9万 USD |
| 営業利益 | −6291.6万 USD | −5475.7万 USD | −6553.1万 USD | −8907.1万 USD | −5802.8万 USD |
| 純利益 | −6784.6万 USD | −5405.4万 USD | −6307.8万 USD | −8680.4万 USD | −5836.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（423.29%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年9月30日 | 1:60 | — | — |
発効済み 2019年9月30日
1:60
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1353.55万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1072.82万0.11%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM890.27万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF523.02万0.01%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO261.26万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO215.17万0.02%139.17億 USD0.24%$356.78+0.94%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP177.31万0.07%26.06億 USD0.20%$66.35+1.13%
Vanguard Health Care ETFVHT132.89万0.01%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
